drugset
Drugs / Cx611
last change Jul 2020 re-read 3 minutes ago

Cx611

Cell therapy

Developed for
bacterial pneumonia · rheumatoid arthritis
Investigated by
Tigenix S.A.U. · Academic Medical Center - University of Amsterdam · Centre Hospital Regional Universitaire de Limoges · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · European Commission · Hospital San Carlos, Madrid

Trials 2

today NCT03158727 · Ph 1/2 NCT01663116 · Ph 1/2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03158727 Jan 2017 → Jul 2020 bacterial pneumonia Tigenix S.A.U. Completed No outcome recorded
Phase 1/2 NCT01663116 Mar 2011 → Jan 2013 rheumatoid arthritis Tigenix S.A.U. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Cx611 “To evaluate the safety and tolerability of the intravenous administration of Cx611, a preparation of allogeneic expanded adipose-derived stem cells (eASCs), in patients with...” PMID 27269294 ↗ Jun 2016
1

NCT03158727 ↗
Modality Cell therapy “Phase Ib/IIa clinical trial of a new medicinal product of the somatic cell therapy class (eASCs).” NCT01663116 ↗
Route Intravenous “the intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells (eASCs) to refractory rheumatoid arthritis (RA) patients” NCT01663116 ↗